Neoadjuvant Hypofractionated Radiotherapy and Chemotherapy in High-Grade Extremity Soft Tissue Sarcomas: Phase 2 Clinical Trial Protocol

Journals

1. Marampon F, Codenotti S, Megiorni F, Del Fattore A, Camero S, Gravina G, Festuccia C, Musio D, De Felice F, Nardone V, Santoro A, Dominici C, Fanzani A, Pirtoli L, Fioravanti A, Tombolini V, Cheleschi S, Tini P. NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. Journal of Cancer Research and Clinical Oncology 2019;145(4):881 View
2. Zaidi M, Ethun C, Tran T, Poultsides G, Grignol V, Howard J, Bedi M, Mogal H, Tseng J, Roggin K, Chouliaras K, Votanopoulos K, Krasnick B, Fields R, Oskouei S, Reimer N, Monson D, Maithel S, Cardona K. Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. Annals of Surgical Oncology 2019;26(11):3542 View
3. Petragnano F, Pietrantoni I, Camero S, Codenotti S, Milazzo L, Vulcano F, Macioce G, Giordani I, Tini P, Cheleschi S, Gravina G, Festuccia C, Rossetti A, Delle Monache S, Ordinelli A, Ciccarelli C, Mauro A, Barbara B, Antinozzi C, Schiavetti A, Maggio R, Di Luigi L, Polimeni A, Marchese C, Tombolini V, Fanzani A, Bernabò N, Megiorni F, Marampon F. Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization. Journal of Biomedical Science 2020;27(1) View
4. Gobo Silva M, Lopes de Mello C, Aguiar Junior S, D'Almeida Costa F, Stevanato Filho P, Santoro Bezerra T, Nakagawa S, Nascimento A, Werneck da Cunha I, Spencer Sobreira Batista R, Nicolau Daher U, Da Cruz Formiga M, Germano J, Catin Kupper B, De Assis Pellizzon A, Lopes A. Neoadjuvant hypofractionated radiotherapy and chemotherapy for extremity soft tissue sarcomas: Safety, feasibility, and early oncologic outcomes of a phase 2 trial. Radiotherapy and Oncology 2021;159:161 View
5. Pomella S, Porrazzo A, Cassandri M, Camero S, Codenotti S, Milazzo L, Vulcano F, Barillari G, Cenci G, Marchese C, Fanzani A, Megiorni F, Rota R, Marampon F. Translational Implications for Radiosensitizing Strategies in Rhabdomyosarcoma. International Journal of Molecular Sciences 2022;23(21):13281 View
6. Vaccaro S, Rossetti A, Porrazzo A, Camero S, Cassandri M, Pomella S, Tomaciello M, Macioce G, Pedini F, Barillari G, Marchese C, Rota R, Cenci G, Tombolini M, Newman R, Yang P, Codenotti S, Fanzani A, Megiorni F, Festuccia C, Minniti G, Gravina G, Vulcano F, Milazzo L, Marampon F. The botanical drug PBI-05204, a supercritical CO2 extract of Nerium oleander, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo. Frontiers in Pharmacology 2022;13 View
7. Potkrajcic V, Traub F, Hermes B, Scharpf M, Kolbenschlag J, Zips D, Paulsen F, Eckert F. Hypofractionated preoperative radiotherapy for high risk soft tissue sarcomas in a geriatric patient population. Radiology and Oncology 2021;55(4):459 View
8. Kao Y. Preoperative ultra-hypofractionation radiotherapy in extremity/trunk wall soft tissue sarcoma — A meta-analysis of prospective studies. Cancer/Radiothérapie 2023;27(2):96 View
9. Bedi M, Singh R, Charlson J, Kelly T, Johnstone C, Wooldridge A, Hackbarth D, Moore N, Neilson J, King D. Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma. Advances in Radiation Oncology 2022;7(3):100850 View
10. Camero S, Cassandri M, Pomella S, Milazzo L, Vulcano F, Porrazzo A, Barillari G, Marchese C, Codenotti S, Tomaciello M, Rota R, Fanzani A, Megiorni F, Marampon F. Radioresistance in rhabdomyosarcomas: Much more than a question of dose. Frontiers in Oncology 2022;12 View
11. Li Z, Xiao K, Niu S, Zhu Q, Xiao Z, Yang P. Comprehensive treatment of primary pelvic synovial sarcoma: A 28-month follow-up case report and review of the literature. Heliyon 2024;10(19):e38807 View